Anglo American rough diamond sales dip year on year

Oliver Haill WebFG News | 20 Jun, 2017 10:45 - Updated: 11:45 | | |

Anglo American mining 285

Anglo American


17:17 12/12/17
  • 7,500.41
  • 0.63%46.93
  • Max: 7,501.52
  • Min: 7,448.31
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 1,542.94
  • 0.79%12.11
  • Max: 1,542.94
  • Min: 1,529.33
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17
  • 16,796.13
  • -0.32%-53.22
  • Max: 16,900.50
  • Min: 16,675.24
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,167.58
  • 0.53%21.93
  • Max: 4,167.95
  • Min: 4,143.15
  • Volume: 0
  • MM 200 : n/a
17:20 12/12/17
  • 4,114.09
  • 0.53%21.50
  • Max: 4,114.10
  • Min: 4,090.46
  • Volume: 0
  • MM 200 : n/a
17:30 12/12/17

The value of Anglo American's rough diamond sales fell 6% year-on-year in the fifth De Beers sales cycle of 2017.

The FTSE 100 group, which earlier this month appointed ex ARM and Tesco board member Stuart Chambers as its new chairman, sold $530m worth of rough diamonds in the sales cycle, up 1.5% on the $522m from the fourth cycle of 2017 but down on the $564m from cycle-five last year.

De Beers chief executive Bruce Cleaver said: "Following positive feedback from the Las Vegas trade show, and in line with recent trends, we saw continued good demand for De Beers rough diamonds in the fifth sales cycle of the year."

The fifth cycle represents provisional sales values as at 19 June 2017, while the fourth cycle from 2017 was restated from the $520m provisionally published in May.

Anglo's diamond production is being boosted by the continued ramp-up of the Gahcho Kué diamond mine in Canada, which has added to its major mines in South Africa, Botswana and Namibia.

In the first quarter, diamond production was up 8% to 7.4m carats, helped by increases in response to improved demand for lower value goods in stock.

More news

22:51 US close: Markets mixed as Fed finishes first day of meeting

Wall Street's main indices finished mixed on Tuesday as the Federal Reserve kicked off its two-day rate-setting meeting, alongside several positive updates from corporate heavyweights such as Boeing and 3M.

22:31 Theresa May unveils new climate change policies in Paris summit

Prime Minister Theresa May has announced new environmental policies including a £140m fund to help developing countries battle against the negative effects of climate change.

18:12 Broker tips: Lloyds, Barclays, Entertainment One

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.

18:07 Results round-up

Industrial equipment rental firm Ashtead said half year earnings were boosted by clean-up efforts after hurricanes Harvey, Irma and Maria and the weak pound as it posted a 16% rise in pre-tax profits to £493.1m.

18:02 Europe close: Technology and M&A power gains in shares

Stocks on the Continent gained ground on Tuesday paced by Technology issues, even as traders waited on the US central bank's policy announcement the next day.

17:53 London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

17:33 US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

17:34 EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

17:49 Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

16:51 GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.